Research programme: cardiovascular disorder therapeutics - Macrophage Therapeutics
Latest Information Update: 18 Jul 2024
At a glance
- Originator Macrophage Therapeutics
- Class Cardiovascular therapies
- Mechanism of Action Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 08 Jul 2024 Preclinical trials in Cardiovascular disorders in USA (unspecified route) prior to July 2024 (Macrophage Therapeutics pipeline, July 2024)